vs
Side-by-side financial comparison of Hologic (HOLX) and Toast, Inc. (TOST). Click either name above to swap in a different company.
Toast, Inc. is the larger business by last-quarter revenue ($1.6B vs $1.0B, roughly 1.6× Hologic). Hologic runs the higher net margin — 17.1% vs 6.2%, a 10.9% gap on every dollar of revenue. On growth, Toast, Inc. posted the faster year-over-year revenue change (22.0% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $178.0M). Over the past eight quarters, Toast, Inc.'s revenue compounded faster (23.3% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Toast, Inc. is an American cloud-based restaurant management software company based in Boston, Massachusetts. The company provides an all-in-one point of sale (POS) system built on the Android operating system.
HOLX vs TOST — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.6B |
| Net Profit | $179.1M | $101.0M |
| Gross Margin | 56.0% | 25.9% |
| Operating Margin | 22.6% | 5.2% |
| Net Margin | 17.1% | 6.2% |
| Revenue YoY | 2.5% | 22.0% |
| Net Profit YoY | -10.9% | 215.6% |
| EPS (diluted) | $0.79 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.6B | ||
| Q3 25 | $1.0B | $1.6B | ||
| Q2 25 | $1.0B | $1.6B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.0B | $1.3B | ||
| Q3 24 | $988.0M | $1.3B | ||
| Q2 24 | $1.0B | $1.2B | ||
| Q1 24 | $1.0B | $1.1B |
| Q4 25 | $179.1M | $101.0M | ||
| Q3 25 | $187.2M | $105.0M | ||
| Q2 25 | $194.9M | $80.0M | ||
| Q1 25 | $-17.4M | $56.0M | ||
| Q4 24 | $201.0M | $32.0M | ||
| Q3 24 | $178.6M | $56.0M | ||
| Q2 24 | $194.5M | $14.0M | ||
| Q1 24 | $169.9M | $-83.0M |
| Q4 25 | 56.0% | 25.9% | ||
| Q3 25 | 55.6% | 26.5% | ||
| Q2 25 | 56.3% | 25.3% | ||
| Q1 25 | 37.5% | 25.9% | ||
| Q4 24 | 56.8% | 24.9% | ||
| Q3 24 | 56.4% | 24.7% | ||
| Q2 24 | 55.4% | 23.0% | ||
| Q1 24 | 53.3% | 23.2% |
| Q4 25 | 22.6% | 5.2% | ||
| Q3 25 | 22.6% | 5.1% | ||
| Q2 25 | 24.9% | 5.2% | ||
| Q1 25 | -0.7% | 3.2% | ||
| Q4 24 | 22.5% | 2.5% | ||
| Q3 24 | 23.3% | 2.6% | ||
| Q2 24 | 24.1% | 0.4% | ||
| Q1 24 | 20.7% | -5.2% |
| Q4 25 | 17.1% | 6.2% | ||
| Q3 25 | 17.8% | 6.4% | ||
| Q2 25 | 19.0% | 5.2% | ||
| Q1 25 | -1.7% | 4.2% | ||
| Q4 24 | 19.7% | 2.4% | ||
| Q3 24 | 18.1% | 4.3% | ||
| Q2 24 | 19.2% | 1.1% | ||
| Q1 24 | 16.7% | -7.7% |
| Q4 25 | $0.79 | $0.18 | ||
| Q3 25 | $0.84 | $0.16 | ||
| Q2 25 | $0.86 | $0.13 | ||
| Q1 25 | $-0.08 | $0.09 | ||
| Q4 24 | $0.87 | $0.09 | ||
| Q3 24 | $0.75 | $0.07 | ||
| Q2 24 | $0.82 | $0.02 | ||
| Q1 24 | $0.72 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $1.4B |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $2.1B |
| Total Assets | $9.2B | $3.1B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $1.9B | $1.2B | ||
| Q1 25 | $1.6B | $1.0B | ||
| Q4 24 | $2.0B | $903.0M | ||
| Q3 24 | $2.3B | $761.0M | ||
| Q2 24 | $2.4B | $691.0M | ||
| Q1 24 | $2.2B | $578.0M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | $2.1B | ||
| Q3 25 | $5.0B | $2.0B | ||
| Q2 25 | $4.8B | $1.8B | ||
| Q1 25 | $4.6B | $1.7B | ||
| Q4 24 | $4.8B | $1.5B | ||
| Q3 24 | $5.1B | $1.4B | ||
| Q2 24 | $5.0B | $1.3B | ||
| Q1 24 | $4.8B | $1.2B |
| Q4 25 | $9.2B | $3.1B | ||
| Q3 25 | $9.0B | $3.0B | ||
| Q2 25 | $8.8B | $2.8B | ||
| Q1 25 | $8.5B | $2.6B | ||
| Q4 24 | $8.7B | $2.4B | ||
| Q3 24 | $9.2B | $2.2B | ||
| Q2 24 | $8.9B | $2.2B | ||
| Q1 24 | $8.7B | $2.1B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $194.0M |
| Free Cash FlowOCF − Capex | $215.2M | $178.0M |
| FCF MarginFCF / Revenue | 20.5% | 10.9% |
| Capex IntensityCapex / Revenue | 1.4% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.28× | 1.92× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $608.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $194.0M | ||
| Q3 25 | $355.1M | $165.0M | ||
| Q2 25 | $343.3M | $223.0M | ||
| Q1 25 | $169.4M | $79.0M | ||
| Q4 24 | $189.3M | $147.0M | ||
| Q3 24 | $367.0M | $109.0M | ||
| Q2 24 | $405.8M | $124.0M | ||
| Q1 24 | $292.4M | $-20.0M |
| Q4 25 | $215.2M | $178.0M | ||
| Q3 25 | $341.4M | $153.0M | ||
| Q2 25 | $330.5M | $208.0M | ||
| Q1 25 | $153.9M | $69.0M | ||
| Q4 24 | $172.5M | $134.0M | ||
| Q3 24 | $350.6M | $97.0M | ||
| Q2 24 | $385.3M | $108.0M | ||
| Q1 24 | $279.6M | $-33.0M |
| Q4 25 | 20.5% | 10.9% | ||
| Q3 25 | 32.5% | 9.4% | ||
| Q2 25 | 32.3% | 13.4% | ||
| Q1 25 | 15.3% | 5.2% | ||
| Q4 24 | 16.9% | 10.0% | ||
| Q3 24 | 35.5% | 7.4% | ||
| Q2 24 | 38.1% | 8.7% | ||
| Q1 24 | 27.5% | -3.1% |
| Q4 25 | 1.4% | 1.0% | ||
| Q3 25 | 1.3% | 0.7% | ||
| Q2 25 | 1.3% | 1.0% | ||
| Q1 25 | 1.5% | 0.7% | ||
| Q4 24 | 1.6% | 1.0% | ||
| Q3 24 | 1.7% | 0.9% | ||
| Q2 24 | 2.0% | 1.3% | ||
| Q1 24 | 1.3% | 1.2% |
| Q4 25 | 1.28× | 1.92× | ||
| Q3 25 | 1.90× | 1.57× | ||
| Q2 25 | 1.76× | 2.79× | ||
| Q1 25 | — | 1.41× | ||
| Q4 24 | 0.94× | 4.59× | ||
| Q3 24 | 2.05× | 1.95× | ||
| Q2 24 | 2.09× | 8.86× | ||
| Q1 24 | 1.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
TOST
| Technology Service | $1.3B | 82% |
| License | $256.0M | 16% |
| Product And Professional Services | $43.0M | 3% |
